Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy ...Middle East

PR Newswire - News
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy - TOKYO, Aug. 27, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and...

Hence then, the article about astellas initiates phase 3 clinical study of fezolinetant for vms in women with breast cancer receiving adjuvant endocrine therapy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News